Endo International (ENDP) Releases FY 2019 Earnings Guidance

Endo International (NASDAQ:ENDP) (TSE:ENL) issued an update on its FY 2019 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of $2.00-2.25 for the period, compared to the Thomson Reuters consensus estimate of $2.17. The company issued revenue guidance of $2.76-2.96 billion, compared to the consensus revenue estimate of $2.87 billion.Endo International also updated its FY19 guidance to $2.00-2.25 EPS.

NASDAQ:ENDP traded down $0.16 during mid-day trading on Thursday, hitting $8.01. The company’s stock had a trading volume of 4,914,842 shares, compared to its average volume of 3,190,015. Endo International has a 1 year low of $5.79 and a 1 year high of $18.50. The firm has a market cap of $1.85 billion, a price-to-earnings ratio of 2.77 and a beta of 1.12.

Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its quarterly earnings results on Thursday, May 9th. The company reported $0.53 EPS for the quarter, beating the consensus estimate of $0.43 by $0.10. Endo International had a negative net margin of 35.00% and a negative return on equity of 337.13%. The company had revenue of $720.00 million for the quarter, compared to analyst estimates of $692.31 million. During the same period in the prior year, the company earned $0.67 earnings per share. The firm’s revenue was up 2.9% on a year-over-year basis. On average, research analysts predict that Endo International will post 2.19 EPS for the current year.

ENDP has been the topic of several recent analyst reports. Leerink Swann lowered shares of Endo International from an outperform rating to a market perform rating in a research note on Tuesday, March 5th. Svb Leerink lowered shares of Endo International from an outperform rating to a market perform rating in a research note on Tuesday, March 5th. ValuEngine raised shares of Endo International from a sell rating to a hold rating in a research note on Tuesday, March 12th. BidaskClub raised shares of Endo International from a hold rating to a buy rating in a research note on Thursday, March 21st. Finally, Zacks Investment Research raised shares of Endo International from a hold rating to a strong-buy rating and set a $11.00 target price on the stock in a research note on Wednesday, January 9th. Two research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and six have given a buy rating to the company’s stock. Endo International has an average rating of Hold and an average target price of $15.44.

ILLEGAL ACTIVITY NOTICE: This report was first published by Baseball Daily News and is the property of of Baseball Daily News. If you are accessing this report on another domain, it was illegally copied and republished in violation of US and international trademark & copyright legislation. The correct version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/05/10/endo-international-endp-releases-fy-2019-earnings-guidance.html.

About Endo International

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.

Featured Story: What strategies should day traders use to execute a trade?

Earnings History and Estimates for Endo International (NASDAQ:ENDP)

Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.